TUSTIN, Calif., Dec. 21, 2011 /PRNewswire/ -- Radient
Pharmaceuticals Corporation (OTCQX:RXPC.PK - News) (OTCPK:RXPC.PK -
News), a developer and marketer of cancer tests, today announces it
has expanded its distribution agreement with UniPharma Taiwan
headquartered in Taipei,
Taiwan.
Previously, Radient's agreement with Uni Pharma provided
UniPharma the exclusive right to distribute Radient's flagship
product Onko-Sure® cancer test in Taiwan. Radient and
UniPharma have now expanded the territory to include Singapore, Hong
Kong and Macau. As a full-service distribution
partner, UniPharma handles regulatory approvals in assigned
territories. Onko-Sure® is a non-invasive in vitro
diagnostic blood biomarker test for cancer.
Uni Pharma will be receiving its first shipment of test kits
this month, December 2011.
With a combined population of over 35 million people,
Taiwan, Singapore, Hong
Kong, and Macau is a
significant health care market. Cancer remains the leading
cause of death in Taiwan,
according to the latest statistics released by the Taiwan
Department of Health on June 15, 2011
(Taiwan Today, June 16 2011).
The most prevalent types of cancer are lung cancer, liver cancer
and colorectal cancer, the three of which were responsible for over
half of all cancer deaths in Taiwan.
"Onko-Sure® is a cost effective, high value In Vitro Diagnostic
cancer test that should be included as a valuable diagnostic
tool by doctors, clinicians, and other oncology healthcare
professionals," stated Terry Lin,
General Manager of UniPharma. "The UniPharma team is excited
to distribute Onko-Sure® in our assigned territories of
Taiwan and now Singapore, Hong
Kong, and Macau. UniPharma has increased its medical
sales team and committed to present at upcoming regional cancer
conferences to increase awareness of Onko-Sure®. UniPharma has
already launched its first Onko-Sure outreach campaign with a booth
at the Taiwan Colorectal Cancer Conference at the Taiwan
International Convention Center (December
9-11) in Taipei."
"Radient welcomes UniPharma's increased commitment to
Onko-Sure®," said the Company's Chairman and CEO, Douglas MacLellan. "We look forward to a
continued, successful working relationship as UniPharma advocates
the use of Onko-Sure in these important health care markets."
About UniPharma Taiwan:
Founded in 1998, UniPharma was established by a group of
professional managers with multi-national pharmaceutical company
backgrounds and extensive experience in the pharmaceutical
industry. Uni Pharma is dedicated to supplying the best
products to patients and delivering the most value to its partners.
Uni Pharma distributes pharmaceutical and medical device
products in Taiwan for nine
international firms from seven countries across the globe.
For more information, visit
http://www.uni-pharma.com/gyhyenglish.html.
About Radient Pharmaceuticals:
Headquartered in Tustin,
California, Radient Pharmaceuticals Corporation is dedicated
to saving lives and money for patients and global healthcare
systems through the deployment of its FDA-cleared In Vitro
Diagnostic Onko-Sure® cancer test kit for colorectal cancer
treatment and recurrence monitoring. The Company's focus is on the
discovery, development and commercialization of unique high-value
diagnostic tests that will help physicians answer important
clinical questions related to early disease state detection,
treatment strategy, and the monitoring of disease progression or
recurrence. Diagnostics are the key to informed treatment
decisions; identifying the right treatment for the right patient
can make all the difference, particularly in cancer patients.
To learn more about our company, products, and potentially
life-saving cancer test, visit www.radient-pharma.com.
Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation
Reform Act of 1995: The statements contained in this document
include certain predictions and projections that may be considered
forward-looking statements under securities law. These statements
involve a number of important risks and uncertainties that could
cause actual results to differ materially including, but not
limited to, the performance of joint venture partners, as well as
other economic, competitive and technological factors involving the
Company's operations, markets, services, products, and prices. With
respect to Radient Pharmaceuticals Corporation, except for the
historical information contained herein, the matters discussed in
this document are forward-looking statements involving risks and
uncertainties that could cause actual results to differ materially
from those in such forward-looking statements.
For additional information on Radient Pharmaceuticals
Corporation and its products visit: www.radient-pharma.com or
www.onko-sure.com or e-mail info@radient-pharma.com. For
Investor Relations contact Paul
Knopick at: pknopick@eandecommunications.com or
949-707-5365.
SOURCE Radient Pharmaceuticals Corporation